Advanced Enzyme Technologies Ltd

Advanced Enzyme Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Advanced Enzyme Technologies Ltd

₹ 370 -5.28%
12 May - close price
advancedenzymes.com BSE: 540025 NSE: ADVENZYMES
About

Advanced Enzyme Technologies Limited is engaged in the business of manufacturing and sales of enzymes.[1]

Key Points

Market Position
The Co. is the 1st Indian enzyme company with 2nd highest market share in India. It is the 2nd listed integrated enzyme player globally. [1]

Website BSE NSE
  • Market Cap ₹ 4,142 Cr.
  • Current Price ₹ 370
  • High / Low ₹ 420 / 252
  • Stock P/E 25.8
  • Book Value ₹ 146
  • Dividend Yield 1.41 %
  • ROCE 13.9 %
  • ROE 10.5 %
  • Face Value ₹ 2.00
Edit ratios

Pros

  • Company is almost debt free.
  • Company has been maintaining a healthy dividend payout of 32.0%

Cons

  • Stock is trading at 2.54 times its book value
  • The company has delivered a poor sales growth of 8.24% over past five years.
  • Company has a low return on equity of 10.4% over last 3 years.
  • Promoter holding has decreased over last 3 years: -6.61%
  • Working capital days have increased from 205 days to 402 days

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Biotechnology

Part of BSE Healthcare Nifty Microcap 250 Nifty Total Market BSE 1000

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026
139 147 158 161 158 155 146 169 167 186 185 172 203
95 103 107 107 102 103 104 114 122 129 124 123 140
Operating Profit 44 44 51 54 55 51 42 55 46 56 60 49 63
OPM % 32% 30% 32% 33% 35% 33% 29% 33% 27% 30% 33% 29% 31%
7 7 6 14 -6 7 10 8 9 9 10 20 7
Interest 1 1 1 1 1 1 1 1 1 1 1 1 1
Depreciation 8 9 9 9 9 9 9 9 10 10 10 10 10
Profit before tax 42 41 48 59 40 49 42 53 43 55 60 58 60
Tax % 24% 29% 27% 28% 25% 28% 21% 27% 38% 26% 25% 26% 24%
32 29 35 42 30 35 33 39 27 40 45 43 45
EPS in Rs 2.87 2.58 3.08 3.74 2.53 3.05 2.94 3.37 2.37 3.57 3.87 3.80 3.84
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
222 293 329 391 420 444 502 529 541 624 637 746
131 155 177 226 236 241 269 327 382 418 441 517
Operating Profit 91 138 152 165 184 203 232 203 158 206 196 229
OPM % 41% 47% 46% 42% 44% 46% 46% 38% 29% 33% 31% 31%
1 -3 3 1 5 6 9 6 21 21 33 46
Interest 9 8 4 9 5 4 3 3 3 4 5 3
Depreciation 9 9 13 18 21 26 28 35 35 35 37 40
Profit before tax 74 118 137 139 162 179 210 171 140 188 187 233
Tax % 31% 35% 32% 33% 28% 26% 28% 28% 26% 27% 28% 25%
51 77 93 94 116 133 151 124 104 137 134 174
EPS in Rs 4.60 6.97 8.20 8.07 9.95 11.58 13.09 10.70 9.45 11.92 11.72 15.07
Dividend Payout % 4% 3% 5% 6% 6% 5% 7% 9% 11% 43% 44% 9%
Compounded Sales Growth
10 Years: 10%
5 Years: 8%
3 Years: 11%
TTM: 17%
Compounded Profit Growth
10 Years: 7%
5 Years: 2%
3 Years: 14%
TTM: 23%
Stock Price CAGR
10 Years: %
5 Years: -4%
3 Years: 8%
1 Year: 25%
Return on Equity
10 Years: 13%
5 Years: 10%
3 Years: 10%
Last Year: 11%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Equity Capital 22 22 22 22 22 22 22 22 22 22 22 22
Reserves 188 256 442 537 657 817 948 1,066 1,213 1,302 1,398 1,610
115 101 54 67 35 28 23 35 34 47 39 32
92 71 65 102 91 104 153 137 142 150 151 175
Total Liabilities 417 450 583 727 805 971 1,146 1,260 1,411 1,521 1,611 1,839
287 285 421 491 495 563 601 619 649 650 679 692
CWIP 5 7 8 11 10 10 10 15 22 41 22 51
Investments 0 0 0 0 111 124 121 102 360 403 480 584
125 158 153 226 188 275 413 524 380 427 430 511
Total Assets 417 450 583 727 805 971 1,146 1,260 1,411 1,521 1,611 1,839

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
54 93 107 116 129 141 163 122 140 141 142 157
-15 -10 -60 -60 -124 -43 -27 2 -286 -65 -89 -74
-36 -63 -65 -2 -43 -39 -26 -48 -26 -59 -73 -70
Net Cash Flow 2 21 -18 54 -38 60 109 75 -171 17 -20 12
Free Cash Flow 42 88 97 105 116 90 143 95 102 94 108 105
CFO/OP 88% 88% 105% 97% 70% 69% 94% 87% 112% 93% 103% 97%

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Debtor Days 61 52 55 55 51 61 63 61 68 58 66 71
Inventory Days 403 358 352 339 363 361 346 402 343 375 378 335
Days Payable 89 68 57 78 46 43 56 60 67 40 41 76
Cash Conversion Cycle 374 342 351 315 369 379 353 404 344 393 403 331
Working Capital Days -43 3 76 47 72 90 94 116 109 102 112 402
ROCE % 25% 36% 31% 25% 24% 22% 22% 16% 12% 15% 13% 14%

Insights

In beta
Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Number of Manufacturing Plants
Number

Log in to view insights

Please log in to see hidden values.

Login
Number of R&D Centers
Number
R&D Spend as % of Sales
%
Fermentation Capacity
m3
Number of Enzymes & Probiotics
Number
Number of Proprietary Products
Number
Capacity Utilization
%
Number of Customers
Number
R&D Expenditure (Percentage of Turnover)
% ・Standalone data

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

4 Recently
Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
46.52% 45.92% 43.62% 43.50% 43.02% 42.95% 42.92% 43.08% 43.08% 43.08% 43.04% 43.26%
21.89% 22.27% 22.54% 23.01% 12.03% 12.63% 12.57% 11.90% 23.45% 25.41% 25.85% 25.50%
7.58% 6.49% 6.98% 7.56% 8.08% 8.02% 8.17% 8.19% 8.45% 6.41% 5.51% 5.41%
24.02% 25.34% 26.88% 25.95% 36.87% 36.40% 36.31% 36.82% 25.00% 25.09% 25.62% 25.85%
No. of Shareholders 75,05272,64273,03468,64065,22266,75867,35165,32267,58969,63768,05166,193

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

DRHP

Credit ratings

Concalls